Asthma & COPD
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Asthma & COPD

on

  • 3,255 views

Asthma & COPD conference taking place June 24-26 in Philadelphia, PA

Asthma & COPD conference taking place June 24-26 in Philadelphia, PA

Statistics

Views

Total Views
3,255
Views on SlideShare
3,254
Embed Views
1

Actions

Likes
0
Downloads
67
Comments
0

1 Embed 1

http://elearning.kctcs.edu 1

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Asthma & COPD Document Transcript

  • 1. Register by April 3rd and SAVE up to $698 Asthma Gain valuable insights into new groundbreaking advances within the respiratory drug development market & COPD TM June 24-26, 2009 Philadelphia, PA See inside for the All-Access Pass discount! Learn from Leading Innovators Including: Heribert Staudinger, PhD, Vice President, Clinical Development, Schering Plough Nestor A. Molfino, MD, Vice President, Clinical Development, Respiratory Diseases, Allergy and Learn Best Practice Strategies On How To: Inflammation, MedImmune Theodore F. Reiss, MD, Vice President of Clinical Assess the need for innovative drug development pipelines in the Research, Merck Research Laboratories • respiratory market Adam Wanner, MD, Professor, Principal Investigator, University of Miami Miller School Uncover modern techniques for formulating a respiratory drug • of Medicine development pipeline Shahin Sanjar, PhD, Head, Pipeline Sourcing, Nycomed US Inc. Discover if we need new bronchodilators and anti-inflammatory • Mark Parry-Billings, PhD, Chief Executive drugs for the treatment of Asthma and COPD Officer, Topigen Pharmaceuticals Develop and enhance product design for addressing patient • Chris O’Brien, PhD, Vice President, Respiratory & Inflammation Therapeutic Area, AstraZeneca adherence and compliance Kevin B. Bacon, PhD, President, Founder and Discover effective strategies for improving the management of • Chief Scientific Officer, Axikin Pharmaceuticals patient care in Asthma Colin Scott, MD, Global Brand Medical Director, Novartis Michael A. McAlexander, PhD, Senior Research Fellow, CEDD, GlaxoSmithKline Media Partners: Lawrence de Garavilla, PhD, Research Fellow, Drug Discovery , Inflammation and Pulmonary Diseases Team, Johnson and Johnson Jonathan E. Phillips, Ph.D, Principal Scientist, Respiratory and Inflammation, Schering-Plough Research Institute Navin L. Rao, PhD, Senior Scientist, Drug www.iqpc.com/us/asthma Discovery, Inflammation, Johnson & Johnson
  • 2. Asthma Gain valuable insights into new groundbreaking advances within the respiratory drug development market & COPD TM June 24-26, 2009 | Philadelphia, PA Who Will you Meet at the Conference? Directors, Heads, Scientists, Chemists, Research Leaders/Fellows/Advisors, & Managers working in the pharmaceutical or Dear Colleagues, biotech industries within: Respiratory Therapeutics • Respiratory diseases including Asth Research & Development • ma are becoming more common, especially in children, therefore the demand for Inflammation • continued development in respirato ry drug Clinical Development discovery and development arena • has grown significantly in recent year s. The Regulatory Affairs • commercial drug development mar ket in this area continues to grow Pulmonology with inhaled • corticosteroid/long-acting bronchod ilator combinations set to be the lead Drug Discovery • ing class by value in 2014, and an estimated 300 million people in the world will be Respiratory Illness • suffering from Asthma, with COPD on the rise. Drug Delivery • Project Management • This year’s timely conference will cove Allergy Therapeutics • r over 16 in-depth sessions and case study examples including: Preclinical Development • Portfolio/Lifecycle Management • • Novel Tech niques for Formulating a Respirato ry Drug Development Pipeline • Differences in the Development of Small vs. Larg e Molecules A special thank you to our • Evolving Clin ical Endpoints in the Developmen t of Inhaled Corticosteroids advisory board • Clinical Out comes of PD4 Inhibitors: Valuable Lessons Learned • Improving the Management of Patient Care Kevin B. Bacon, PhD, President, Founder and in Asthma Chief Scientific Officer, Axikin • Developing Product Design for Addressing Patie nt Adherence and Compliance Pharmaceuticals Heribert Staudinger, PhD, Vice President, And much more including 4+ hou Clinical Development, Schering Plough rs of scheduled networking, insightfu l interactive panel discussions and a series of inte Shahin Sanjar, PhD, Head, Pipeline Sourcing, ractive workshops. Nycomed US Inc. Mark Parry-Billings, PhD, Chief Executive Engage in dynamic conversation with your industry peers at our multiple Officer, Topigen Pharmaceuticals networking sessions and work closely with man y respiratory drug discovery and deve Ewan Walters, PhD, Medical Director, Teva UK lopment industry leaders including AstraZen eca, Merck, Johnson & Johnson, Med Dzelal Serdarevic, PhD, Director, A&R Immune, Schering Plough, Nycomed, GlaxoSm Therapeutic Area, Clinical R&D, Pfizer ithKline, Novartis and many more, including a series of medical device designers, Reza Farienfar, Director, Business delivery experts and academic part icipants. Be sure to register yourself and a team Development, Cardinal Health of key people for this important even t today! Gerhard Scheuch, PhD, Chief Executive Officer, Activaero GmbH We look forward to seeing you in Philadelphia in June! Best Regards, Sponsorship and Exhibition Opportunities teractive P . - Highly in Sponsorships and exhibits are excellent .S opportunities for your company to showcase its e and informativ products and services to high-level, targeted rence decision-makers attending the Asthma & COPD post-confe e page 5 Summit. IQPC and Pharma IQ help companies like workshops! Se Simon Curtis yours achieve important sales, marketing and branding objectives by setting aside a limited for details. Conference Director number of event sponsorships and exhibit spaces – www.iqpc.com/us/asthma all of which are tailored to assist your organization in creating a platform to maximize your exposure at the event. For more information on sponsoring or exhibiting at the Asthma & COPD Summit please contact Mario Matulich at (212) 885-2719 or sponsorship@iqpc.com. 1-800-882-8684 • www.iqpc.com/us/asthma 2
  • 3. Main Conference Day One Wednesday, June 24, 2009 Registration and Coffee Evaluating high resolution CT scans • 8:00 Identifying newer endpoints for evaluation • Welcome Address and Chairman’s Opening Remarks Kevin B. Bacon, PhD, President, Founder and Chief Scientific Officer, 8:50 Axikin Pharmaceuticals Opening Keynote Presentation: Novel Techniques for Heribert Staudinger, PhD, Vice President, Clinical Development, 9:00 Formulating a Respiratory Drug Development Pipeline Schering Plough Fred Bode, PhD, Director, Respiratory Sciences, Sepracor* Accelerating the drug development pipeline • Shahin Sanjar, PhD, Senior Director, Respiratory Sciences, Nycomed Identifying a set of promising candidate projects addressing gaps in several • stages of the drug development pipeline from fundamental research to Evolving Clinical Endpoints in the Development of 2:15 product Inhaled Corticosteroids Evaluating strategies for generating large numbers of molecular targets for • Discussing development of inhaled corticosteroid/long-acting beta- • drugs as well as novel molecules to attack new and existing drug targets agonist combinations • Generating the interest and funding that will move a compound along • Overviewing clinical endpoints the path to eventual therapeutic approval • Addressing and understanding beta-agonist safety issues/patient Theodore F. Reiss, MD, Vice President of Clinical Research, Merck monitoring Research Laboratories • Examining endpoint case study examples Panel Discussion: Understanding and Assessing the Need • Discussing the development of NMEs in asthma and COPD 9:45 for New Drug Development Pipelines in the Respiratory • Discovering if we need new bronchodilators and anti-inflammatory Market drugs for the treatment of asthma and COPD Heribert Staudinger, PhD, Vice President, Clinical Development, Examining pipeline pitfalls from the past: What to be aware of? • Schering Plough Overviewing new respiratory therapeutic approaches: Strategies for • predicting clinical success or failure Networking Break 3:00 • Investigating compounds which may help improve control of asthma exacerbations while reducing the need for steroids and rescue medication The Promise of PDE4 Inhibitors as Novel Anti- 3:30 • Evaluating the need to find novel anti-inflammatory drugs to treat COPD Inflammatory Agents in COPD: Valuable Lessons Learnt to reduce exacerbations, disease progression and mortality From Clinical Studies • Discussing and predicting the future direction of the respiratory drug Discussing what we can learn from animal models of COPD • discovery and development market Identifying what we have learnt from clinical studies with PDE4 • Nestor A. Molfino, MD, Vice President, Clinical Development, Respiratory inhibitors Diseases, Allergy and Inflammation, MedImmune • Choosing appropriate endpoints to reflect the drug mode of action Mark Parry-Billings, PhD, Chief Executive Officer, Topigen • Treating systemic or lung disease Adam Wanner, MD, Professor, Principal Investigator, University of • Examining the place of anti-inflammatory therapy in COPD Miami Miller School of Medicine Shahin Sanjar, PhD, Head, Pipeline Sourcing, Nycomed US Inc. Networking Break 10:30 Application of Antisense Oligonucleotides in Asthma 4:15 and COPD (Case Study) Differences in the Development of Small vs. Large 11:00 Molecules Examining oligonucleotide therapeutics in respiratory disease • Displaying rationale for using a multi-target approach in asthma and • Summarizing the main differences between small molecules and large • COPD molecules • Designing and pre-clinical screening of effective drug candidates • Reviewing of preclinical approaches • Discussing clinical positioning and findings • Understanding of main differences in clinical development programs Mark Parry-Billings, PhD, Chief Executive Officer, Topigen • Exploring if combination of large and small molecules is feasible • Comprehending the major bottlenecks in overall development COPD: New Lessons from Alpha-1 Antitrypsin 5:00 Nestor A. Molfino, MD, Vice President, Clinical Development, Respiratory Deficiency (Case Study) Diseases, Allergy and Inflammation, MedImmune Appreciating the global COPD problem and the lack of disease- • Functional Endpoints in Asthma modifying drug therapy for COPD 11:45 • Understanding that alpha-1 antitrypsin deficiency, a rare genetic Discussing lung function use as a primary endpoint in asthma clinical trials • disease with a well characterized pathogenesis, has the same Discussing relationships between, traditional and patient-centered end- • pulmonary phenotype as common COPD and therefore can serve as points during treatment with different classes of medication an experiment of nature to study the pathogenesis of common COPD • Examining severe asthma indicated by poor lung function, frequent • Appreciating the fact that the concept of protease-antiprotease symptoms or reliever use, night waking and exacerbations imbalance, thought to be shared by alpha-1 antitrypsin deficiency and • Understanding the relationship between end-points and medication class common COPD, has not resulted in effective drugs for COPD • Identifying novel functional endpoints in Asthma with case study • Becoming familiar with protein misfolding, aggregation and disposal, examples a new link between alpha-1 antitrypsin deficiency and common COPD Chris O’Brien, PhD, Vice President, Respiratory & Inflammation Therapeutic • Understanding that pharmacologically targeting protein misfolding Area, AstraZeneca and trafficking could lead to the development of novel drugs for both Networking Lunch alpha-1 antitrypsin deficiency and common COPD 12:30 Adam Wanner, MD, Professor, Principal Investigator, University of Panel Discussion: Improving Endpoints in COPD Drug Miami Miller School of Medicine 1:30 Development End of Day One 5:45 Discussing the pros and cons of improved X-Ray analysis • 1-800-882-8684 • www.iqpc.com/us/asthma 3
  • 4. Main Conference Day Two Thursday, June 25, 2009 Registration and Coffee Novel Ion Channel Drug Development Strategies 8:00 1:30 for the Treatment of COPD Symptoms Welcome Address and Chairman’s Opening 8:50 Displaying the use of RNA interference for in vivo pre-clinical • Remarks validation of ion channel targets in non-mouse species • Understanding automated patch-clamp and baculovirus-based Developing Product Design for Addressing Patient 9:00 vectors for transient transfection as enabling technologies for Adherence and Compliance ion channel drug discovery Retaining current patients as costs six times more to attract • Discussing recent insights into the molecular biology and • new patients function of the airway nociceptor and its links to cough, • Discovering and uncovering specific design requirements for dyspnea and other respiratory symptoms tackling adherence and compliance • Examining tetrodotoxin-resistant sodium channels and transient • Understanding which medical device designer and receptor potential channels as emerging therapeutic targets for manufacturer is a good fit for your product, and why chronic respiratory diseases • Applying sophisticated analytical processes to quantify the sales • Identifying translational aspects of targeting ion channels for impact of specific marketing programs for product brands COPD symptom relief • Examining product design success stories and case study M. Allen McAlexander, PhD, Investigator, Respiratory CEDD, examples post patient usage GlaxoSmithKline Please check the website for speaker updates. Formulation, Generation and Delivery of 2:15 Improving the Management of Patient Care in Respiratory Therapeutic Aerosols to Rodents 9:45 Asthma Discussing the use of animal disease models as a tool for • Improving communication and understanding between patients assessing efficacy of inhaled pre-clinical drug candidates • and physicians • Overview of instrumentation necessary to deliver dry powder • Examining patient suggestions for improvements aerosols to rodents and estimated the dose delivered to the • Improving education around the illness and treatment lungs • Discussing the benefits of more than one pharmacological • Identifying ideal properties of inhaled respiratory drugs approach • Displaying case study examples of using this model with clinical Colin Scott, MD, Global Brand Medical Director, Novartis standard inhaled steroids Jonathan E. Phillips, Ph.D, Principal Scientist, Respiratory Drug 10:30 Networking Break Discovery, Schering-Plough Research Institute 11:00 Novel Inhaled Drug Delivery Technology Networking Break 3:00 • Evaluating the effectiveness of Inhalation of bronchodilators Leukocyte Proteases in Airways Diseases (Case and glucocorticosteroids 3:30 Study) • Minimizing local (oropharyngeal) and systemic side-effects of drugs Protease-protease inhibitor imbalance contributes to airways • • Uncovering simple to use, portable, durable, unobtrusive and diseases such as asthma and COPD cost effective medical device aspects • Neutrophil derived Cathepsin G and mast cell derived chymase • Examining the pros and cons of the pressurized metered-dose and tryptase may be key enzymes contributing to these inhaler (pMDI) - The most widely used delivery system diseases • Discussing the increased-use of DPIs (Dry-powder Inhalers) to • Small molecule inhibitors of these enzymes have anti- deliver asthma medications inflammatory properties and are effective in preclinical models Please check the website for speaker updates. of airways diseases Lawrence de Garavilla, Ph.D., Research Fellow, Inflammation 11:45 Using Patents Strategically in Respiratory Product and Pulmonary Diseases Team, Drug Discovery, Johnson & Lifecycle Management Johnson Pharmaceutical Research and Development, L.L.C. Learning how innovators and generics are using patents to • Leukotriene A4 Hydrolase Inhibitors and Airway manage lifecycles 4:15 Inflammation (Case Study) • Discussing patents on combination drugs in the current environment Overview of leukotriene A4 hydrolase biology • • Using novel delivery systems—both pharmaceutical and Efficacy of leukotriene A4 hydrolase inhibitors in preclinical • devices—as a basis for patent protection airway inflammation models • Getting competitive intelligence, patent strategy, and product • Understanding the role of leukotrienes in chronic airway strategy to work together models Bruce D. Sunstein, Co-founder, Partner, • Displaying mechanisms of action of leukotriene A4 hydrolase Bromberg & Sunstein LLP inhibitors Navin L. Rao, PhD, Senior Scientist, Drug Discovery, 12:30 Networking Lunch Inflammation, Johnson & Johnson End of Conference & Chairman’s Closing Remarks 5:00 1-800-882-8684 • www.iqpc.com/us/asthma 4
  • 5. Post-Conference Workshops Friday, June 26, 2009 9:00 am – 12:00 pm (Registration at 8:30 am) Coffee will be served 12:30 pm – 3:00 pm (Registration at 12:00 pm) Lunch included A B The Effective Use of Biomarkers in Asthma and Allergy issues: Addressing Respiratory Drug Discovery Approaches to Allergic Disorders Studying clinical effects of new therapies on patients through Currently within the respiratory arena, there have been modern electronic monitoring of lung function (FEV1) as well as misconceptions why asthma–related drug development advanced lung function and exercise and challenge test has programs have not been pursued commercially in the form of become possible. As a result of this., respiratory drug tackling other similar allergy-therapeutic disorders. Given that, development companies are employing human whole blood there are many similarities between both asthma-based drug flow cytometry and non-invasive sampling to assess therapeutics and many allergy-based drug development pharmacodynamic effects of new therapies in phase I/II clinicial programs. This workshop will uncover and overview some of the studies. Surrogate biomarkers in COPD may be assessed in novel approaches to these new drug development pipelines blood, exhaled breath, induced sputum, bronchial mucosal focused on allergy therapeutics, and identify some of the most biopsy, bronchoalveolar lavage (BAL), and through advanced commercially viable pipelines currently in development. radiographic imaging. What will be covered: What will be covered: • Displaying novel approaches for identifying genes responsible • Making a suited claim to the FDA for therapeutic purposes for allergic disorders • Identifying and understanding new biotechnology agents and • Discussing standardized immuno-therapeutic approaches for biomarkers for asthma allergies • Studying clinical effects of new therapies on patients through • Evaluating unorthodox testing methods: electronic monitoring of lung function (FEV1) 1. Vega (electro-diagnostic) testing • Employing human whole blood flow cytometry and non- 2. Cytotoxic testing (quot;Bryan's testquot;) and the Alcat test invasive sampling to assess pharmacodynamic effects of new 3. Iridology therapies in phase I/II clinical studies 4. Kinesiology • Relying on a collaboration between academics in clinical 5. IgG food antibody testing and other techniques research, the pharmaceutical industry and regulatory • Developments in allergy elimination techniques - allergen authorities immunotherapy • Uncovering the link between allergic disorders and asthma Workshop Leaders: approaches Yi Wang, PhD, Head, Preclinical Sciences, Alexion Pharmaceuticals Please check the website for up-to-date details about Marianne Mann, MD, Clinical & Regulatory Drug Development the workshop. Consultant Please check the website for up-to-date details about the workshop. About the Media Partners A major STM publisher, Bentham Science answers the information needs for the pharmaceutical, Bio-medical and medical research community. Leading journals include Current Pharmaceutical Design (Impact Factor 4.8) and Current Medicinal Chemistry (Impact Factor 4.9) FREE online journals & information: www.bentham.org Since 1999, PharmiWeb.com has been bringing the latest news and developments in the pharmaceutical industry to a global audience, now reaching close to a quarter of a million professionals. Sponsored by many of the world’s leading pharmaceutical corporations, PharmiWeb.com is widely regarded as the leading pharma portal. To find out more about PharmiwWeb.com, and the other offerings from PharmiWeb solutions, please visit www.pharmiwebsolutions.com. Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries nearly 10,000 English language titles including, market reports, studies and books and is the UK's largest online biopharma information store. www.piribo.com Report Buyer is the intelligent way to buy market research online. Browse and choose from a current and comprehensive range of specialised intelligence from leading publishers covering most industry and market sectors. Trusted by information professionals across the world, Report Buyer’s mission is to help you find the right business intelligence. www.reportbuyer.com 1-800-882-8684 • www.iqpc.com/us/asthma 5
  • 6. Asthma Gain valuable insights into new groundbreaking advances within the respiratory drug development market & COPD TM June 24-26, 2009 Philadelphia, PA REGISTRATION CARD (Email this form to info@iqpc.com or fax to 646-378-6025) YES! Please register me for ❑ Conference Only ❑ All-Access Pass ❑ Workshops Name ____________________________________________________________ Job Title _________________________________________________ Organization______________________________________________________ Approving Manager________________________________________ Address _____________________________________________ City________________________________________State__________Zip__________ Phone_____________________________________________E-mail____________________________________________________________________ ❑ Please keep me informed via email about this and other related events. ❑ Check enclosed for $_________ (Payable to IQPC) ❑ Charge my ❑ Amex ❑ Visa ❑Mastercard ❑ Diners Club Card #_______________________________Exp. Date___/___ ❑ I cannot attend, but please keep me informed of all future events. Registration Information Qualified Pharmaceutical and Biotech Organizations: PRICING Register by April 3, 2009 Register by April 17, 2009 Register by May 1, 2009 Register by May 29, 2009 Standard Price Conference Only $1,199 (save $400) $1,299 (save $300) $1,399 (save $200) $1,499 (save $100) $1,599 All-Access Pass $1,999 (save $698) $2,099 (save $598) $2,199 (save $498) $2,299 (save $398) $2,399 (save $298) Workshops $549 each $549 each $549 each $549 each $549 each Others: PRICING Register by May 1, 2009 Register by May 29, 2009 Standard Price Conference Only $1,999 (save $600) $2,299 (save $300) $2,599 All-Access Pass $2,899 (save $798) $3,199 (save $498) $3,499 (save $198) Workshops $549 each $549 each $549 each See website at www.iqpc.com/us/asthma for an explanation of a Qualified Pharmaceutical and Biotech Organizations. Please note multiple discounts cannot be combined. Reference: Please include the name of the attendee(s) and the event number: 17336.001 A $99 processing charge will be assessed to all registrations not Payment Policy: Payment is due in full at the time of registration and includes lunches, refreshment accompanied by credit card payment at the time of registration. and detailed conference materials. Your registration will not be confirmed until payment is received and may be subject to cancellation. MAKE CHECKS PAYABLE IN U.S. DOLLARS TO: IQPC * CT residents or people employed in the state of CT must add 6% sales tax. For IQPC’s Cancellation, Postponement and Substitution Policy, please visit www.iqpc.com/cancellation TEAM DISCOUNTS or information on team discounts, please contact IQPC Customer Service at Note: Conference venue to be confirmed shortly. Please check www.iqpc.com/us/asthma for updated 1-800-882-8684. Only one discount may be applied per registrant. information. Special Discounts Available: A limited number of discounts are available Special Dietary Needs: If you have a dietary restriction, please contact Customer Service at 1-800-882- for the non-profit sector, government organizations and academia. For more 8684 to discuss your specific needs. information, please contact customer service at 1-800-882-8684. ©2009 IQPC. All Rights Reserved. The format, design, content and arrangement of this brochure Details for making payment via EFT or wire transfer: constitute a trademark of IQPC. Unauthorized reproduction will be actionable under the Lanham Act JPMorgan Chase - Penton Learning Systems LLC dba IQPC: 957-097239 and common law principles. ABA/Routing #: 021000021 1-800-882-8684 • www.iqpc.com/us/asthma 6